GILD
$71.21
Gilead Sciences
$.29
.41%
GILD
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $1.63
Revenue:  $5.48 Bil
Thursday
Jan 24
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when GILD reports earnings?
Beat
Meet
Miss

Where is GILD's stock price going from here?
Up
Flat
Down
Stock chart of GILD
Analysts
Summary of analysts' recommendations for GILD
Score
Grade
Pivots
Resistance
$74.45
$73.50
$72.21

$71.26

Support
$69.97
$69.02
$67.73
Tweet
Growth
Description
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Peers
BiogenAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenSangamo TherapeuticsBio-Techne